← Analysis page  ·  Steve Eisman hub  ·  Research hub

Actionable insights — Earnings Keep the Market Strong Despite Signs of Consumer Weakness

The repeatable analysis behind the calls: not what he rates, but how he reads it — written so the process can be rerun later on different names and quarters.
2026-MAY-01 · The Real Eisman Playbook — "The Weekly Wrap" · Steve Eisman (ex-Neuberger Berman PM) · ▶ Watch · full analysis · transcript
How to read this page: each insight is a method — the question he asks of a print, the valuation frame behind a pick, the cross-check on the consumer or the credit. The boxed line shows how it played out in this appearance. Timestamps deep-link into the video.

3:02 1. Guard against thesis creep — re-underwrite, don't re-rationalize

The repeatable method
  1. When a position drops hard, separate the price action from the thesis. Write down the original thesis verbatim before reacting.
  2. Ask only: did this quarter break a load-bearing pillar of that thesis, or just hit a data point investors fixate on? If the pillars hold, the drop is an entry, not an exit.
  3. Refuse to quietly edit the thesis to fit the new price ("have the tail wag the dog"). Either the pillars are intact (add/hold) or one broke (sell) — no middle "it's complicated."
Here: CHTR −25% on a 120k broadband-sub loss — but the two pillars (CapEx rolling off into FCF/buybacks; cheapest converged bundle) were untouched, so he added on the dip (5:48).
Watch for

3:24 2. The CapEx-rolloff → FCF → buyback engine — value a self-liquidating cheap stock

The repeatable method
  1. Find a company finishing a multi-year capital build whose CapEx is scheduled to fall sharply. Each dollar of declining CapEx drops "dollar for dollar" into free cash flow.
  2. Map the outer-year FCF against the current market cap to get a free-cash-flow yield (FCF ÷ market cap). A double-digit-plus yield with a tiny cap means the buyback can retire a huge share of the float.
  3. Frame the disconnect explicitly: at the current price the market must be implying either CapEx won't fall, buybacks won't happen, or earnings collapse. If none is credible, the stock is mispriced — but accept "cheap can stay cheap," so size it as a wait.
  4. Demand a low-cost competitive edge so the operating business doesn't erode while you wait.
Here: CHTR — CapEx 11B→9.5B→7.5–8B (2026–29), ~70% FCF yield in the outer years on a $23B cap, buying back up to 50% of shares; edge = $100 converged bundle vs $180–200 rivals; 2026 PE ~4×.
Watch for

14:52 3. The cheap-stock turnaround template — find the analog that already worked

The repeatable method
  1. For a contested cheap-stock turnaround, point to a completed precedent: a name that was equally cheap and hated, then "started to perform" and re-rated multiples-fold.
  2. Confirm the precedent is performing on fundamentals (beats across the board + raised guidance), not just multiple expansion, so the analogy is operational, not hopeful.
  3. Use it to set the payoff shape for the open idea — what "it works" looks like in price terms.
Here: GM $27 (Nov 2023) → $78, beating across the board (rev 43.6B, EPS 3.70 vs 2.60) with raised guidance, is the template "for what I'm hoping for with Charter."
Watch for

13:38 4. Read the K-shaped consumer through cheap-staple same-store sales

The repeatable method
  1. Pick a low-ticket, everyday brand (pizza, fast food) as the bottom-of-the-K gauge — when even cheap discretionary softens, the lower/middle consumer is stressed.
  2. Read its same-store sales (sales at locations open ≥1 yr) vs estimate — the single cleanest retail-health metric — alongside EPS direction.
  3. Triangulate against a top-of-the-funnel spending read (a card network) to confirm the split: aggregate spend strong while the value brand is weak = K-shaped, not broad recession.
Here: DPZ SSS +0.9% vs 2.3% est, EPS −5%, −8% → "bottom of the K… in a deep recession," even as V net rev +17% / payment volume +9% says the overall consumer still spends.
Watch for

11:26 5. The refinancing-not-the-mark question — stress private-credit software loans by the equity cushion

The repeatable method
  1. Distrust lender "risk buckets" that only say borrowers are current now ("low risk" ≠ refinanceable). Ask the forward question: who refinances this loan at maturity?
  2. Proxy the private-equity-owned borrower's equity value with a comparable public peer's drawdown. If the public comp is down ~60%, assume the private equity cushion is worth <½ original cost.
  3. When the equity beneath a loan is worth less than half, flag refinancing risk for the whole BDC/private-credit chain regardless of current marks.
  4. Cross-check the manager's own quality: a negative direct-lending quarter, heavy add-back-driven "adjusted" earnings, and GAAP-thin profitability are tells the reported numbers flatter reality.
Here: NOW −60% as the software proxy → ARCC's 85% "low-risk" software loans likely sit on <½-cost equity; OWL direct lending −40bps, $196M stock comp (50% over consensus), "barely profitable" under GAAP.
Watch for

18:21 6. Quantify the pricing-war wipeout — model the unit economics, not the guidance

The repeatable method
  1. When a regulator is about to clear a cheaper substitute, ignore management's "we won't lose share" and build the buyer's actual per-unit cost both ways.
  2. Use the real funnel (e.g. ~30% of mortgage applications fund) so per-funded-loan fees get weighted correctly, then compute total cost per 100 transactions for each product.
  3. If the ratio is lopsided (here ~20×), treat "won't lose share" as the high-risk assumption and the regulatory-approval + pilot/rollout calendar as the catalyst path.
  4. Flag structural conflicts that worsen the odds (a monopoly buying inputs from the very competitors now undercutting it).
Here: FICO Score 10 T = $2,049 per 100 apps (99¢×100 + $65×30) vs VantageScore $99 — a 20-to-1 gap; FHFA approval in months, pilots 2026 / full 2027; FICO pulls data from the three bureaus it now competes with. Short for several months.
Watch for

20:38 7. The "lacks a thesis" filter — require a reason to move before owning a fallen stock

The repeatable method
  1. For a beaten-down name, separate "cheap" from "investable." A multi-year price collapse plus "in line" guidance with no sign of improvement is not a setup.
  2. State the missing piece plainly: with no identifiable catalyst or reason the business inflects, there is no thesis — and "an inexpensive stock does not necessarily make a good investment."
  3. Pass until a concrete reason to re-rate appears; don't buy hope every quarter.
Here: ENPH $335 (2022) → $33, EPS −31%, Q2 guide "in line" but no improvement — "the stock lacks a thesis," so there's no case to own it (contrast with CHTR, which has an explicit one).
Watch for

9:20 8. Watch the concentration tells — semis weight and the single-headline tape

The repeatable method
  1. Track a single subsector's share of the index against its own history; an all-time-high weight means index-level moves are hostage to that one theme's news.
  2. Confirm the fragility on the tape: a lone story (e.g. one AI revenue/data-center headline) producing a one-day correction across semis, infotech and the Nasdaq proves the concentration.
  3. Note the non-confirmations that complicate the macro narrative (an asset not behaving per its textbook role) and keep them on a watch-list rather than forcing a conclusion.
Here: semis a record 16% of the S&P (46% of infotech), software down to 8% from 12% (Aug 2025); a single WSJ OpenAI story sparked a one-day semi/Nasdaq correction; gold "did nothing" during the war — "I'm not sure what this means, but it's worth watching."
Watch for

Methods distilled from the public YouTube video (transcript in transcript.txt) for personal study. Not investment advice. © The Real Eisman Playbook / Steve Eisman for source material.